Inclusion Criteria:

          -  1. Subjects who are fully informed of the purpose, nature, method and possible adverse
             reactions of the study, and are willing to participate in the study and sign the
             informed consent document prior to any procedure; 2. Aged between 18 to 75 years old,
             male or female when sign the informed consent form (ICF); 3. Subjects must have
             histological or cytological confirmation of recurrent or refractory CLDN18.2-positive
             advanced solid tumors including but not limit to gastric and gastroesophageal junction
             adenocarcinoma, pancreatic carcinoma, biliary tract carcinoma, colorectal carcinoma,
             ovarian carcinoma; 4. Subjects are intolerable for available standard therapy or there
             is no standard available therapy; 5. Eastern Cooperative Oncology Group (ECOG)
             performance status of 0-1 with no deterioration within 2 weeks from the first dose; 6.
             Life expectancy ≥ 3 months; 7. Tumor samples have CLDN18.2 membranous staining in ≥ 1%
             of the tumor cells with any intensity as determined by central immunohistochemistry
             (IHC) testing. As such, all patients must be able to provide formalin fixed and
             paraffin embedded archived tumor tissue samples obtained ≤ 3 years prior to screening;
             8. Subjects must have the following organ and marrow function in laboratory tests
             within 7 days from the first dose:

               1. PLT ≥ 90 × 109/L; ANC ≥ 1.5 × 109/L; Hemoglobin ≥ 9 g/dL, without receiving EPO,
                  G-CSF, or GM-CSF within 14 days and blood transfusion in at least 7 days;

               2. Coagulation function: INR ≤ 1.5; APTT ≤ 1.5 × ULN;

               3. Liver function: Bilirubin ≤ 1.5 × ULN (Subjects with Gilbert's Syndrome are
                  allowed if direct bilirubin is within normal limits); AST and ALT≤ 2.5 × ULN
                  without liver metastases (≤ 5 × ULN if liver metastases are present); Albumin ≥
                  2.5 g/dL;

               4. Kidney function: Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 50
                  mL/min (using Cockcroft-Gault formula, see Appendix 2); Qualitative urine protein
                  ≤ 1+ or qualitative urine protein ≥ 2+, but 24-hour urine protein < 1g;

               5. Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50%, QT interval
                  (QTcF) ≤ 470 ms.

                  9. Subjects who are able to well communicate with investigators as well as
                  understand and adhere to the requirements of this study.

                  Exclusion Criteria:

                    1. Subjects who have difficulties in venous blood collection or history of
                       dizziness with blood or needles;

                    2. Childbearing potential female (see Appendix 3 Contraceptive Methods) who
                       have positive pregnancy test or are breast feeding;

                    3. Subjects who known to be allergic to LM-102 or any of its excipients;

                    4. Exposure to any IMP, or participate in any other clinical trial within 28
                       days prior to 1st dosing LM-102;

                    5. Subjects with prior anti-tumor within 28 days prior to 1st dosing of LM-102,
                       including radiotherapy (except palliative radiotherapy, beyond 14 days prior
                       to 1st dosing of LM-102, and the toxicity has been recovered as assessed by
                       investigator.), chemotherapy, biotherapy, endocrine therapy and
                       immunotherapy, etc. However, the application of other small molecular
                       targeted drugs and the herbal medicine with anti-tumor indication longer
                       than 14 days or 5 half-life periods of the drug (whichever is longer) is
                       acceptable;

                    6. Subjects who have received surgical or interventional treatment within 28
                       days prior to 1st dosing LM-102, excluding operations or surgeries that can
                       be recovered within 14 days prior to 1st dosing LM-102, and have been
                       recovered by the investigator's assessment, e.g., tumor biopsy, puncture,
                       palliative operation, rectal/gastrostomy, etc.;

                    7. Subjects who have concurrent administration of anticoagulation agents or
                       vitamin K antagonists;

                    8. Subjects who have concurrent administration of therapeutic doses of heparin
                       (prophylactic doses are acceptable);

                    9. Subjects who have gastric outlet obstruction, persistent recurrent vomiting
                       or uncontrolled/significant gastrointestinal hemorrhage, symptomatic peptic
                       ulcer, or major bleeding risk in other parts of the body within 28 days
                       prior to 1st dosing LM-102;

                   10. Central nervous system metastasis or meningeal metastasis with clinical
                       symptoms, or other evidence that the subject's central nervous system
                       metastasis or meningeal metastasis has not been controlled, and the
                       investigator judges it to be unsuitable for inclusion;

                   11. Subjects who have symptomatic congestive heart failure, history of
                       congestive heart failure greater than New York Heart Association (NYHA)
                       Class II, unstable angina pectoris, uncontrolled hypertension (Blood
                       pressure still ≥ 140/90 mmHg after drug treatment), clinically significant
                       cardiac arrhythmia or myocardial infarction within the past 6 months, etc.;

                   12. Any adverse events from prior anti-tumor therapy have not yet recovered to ≤
                       grade 1 of CTCAE v5.0 (Except for some grade 2 toxicity that the
                       investigator judges that there is no safety risk, such as alopecia, and
                       other long term ≤ grade 2 toxicities which would not impact the
                       administration of LM-102 and safety evaluation);

                   13. Subjects who have uncontrolled or severe illness, including but not limited
                       to ongoing or active infection requiring antibiotics;

                   14. Subjects who have a history of immunodeficiency disease, including other
                       acquired or congenital immunodeficiency diseases, or organ transplantation,
                       or allogeneic bone marrow transplantation, or autologous hematopoietic stem
                       cell transplantation;

                   15. HIV infection, active HBV infection (HBV DNA exceeds the ULN), active HCV
                       infection (HCV RNA exceeds the ULN);

                   16. Male and female subjects who are unwilling to use adequate contraceptive
                       methods (e.g, concomitant use of a spermicidal agent, barrier contraceptive,
                       or/and intrauterine contraceptive during the study and for at least 6 months
                       after the last dose of LM-102. (See Appendix 3 for contraceptive methods);

                   17. Subjects who have psychiatric illness or social situations that would
                       preclude study compliance;

                   18. Subjects who have another active malignancy which is likely to require
                       treatment;

                   19. Subject who is determined as not eligible to participate in this study by
                       the investigator.